Company intelligence / Profile preview
BioNet
Ayutthaya, Ayutthaya, Thailandbionet.one ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Commercial
01
Overview
BioNet is the only company with a licensed recombinant pertussis vaccine containing genetically inactivated pertussis toxin. It has successfully commercialized this product globally. The company is advancing next-generation mRNA-based vaccines including a pancoronavirus candidate. It recently signed an MoU with PT Bio Farma to expand access to its TdaP vaccine across ASEAN countries.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant protein vaccinesmRNA-based drugs/Vaccine
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
PT Bio Farma (Indonesia’s state-owned vaccine manufacturer) – strategic MoU for regional distribution of combined TdaP vaccine in ASEAN.Other partnerships not detailed but implied global network.
Beyond the preview
Go deeper on BioNet.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioNet.